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Abstract The main ligand-binding determinant of the human 
urokinase receptor (uPAR) is located in the amino terminal 
domain D1, but when isolated this domain presents a 1500 fold 
lower affinity than the intact three-domain uPAR (DID2D3) [1]. 
uPAR mutants missing either domain 2 (D1HD3) or domain 3 
(DID2) were expressed in murine LB6 cells and showed to be 
properly GPI-anchored to the cell surface. Binding assays with 
[tzSI]ATF demonstrated that these mutants possessed a normal 
(DID2) or slightly reduced (D1HD3) affinity, indicating that a 
high ligand-affinity may be achieved by a combination of D1 with 
domain D2 or D3. 
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I. Introduction 
Binding of urokinase plasminogen activator (uPA) to its 
specific high-affinity receptor (uPAR) profoundly affects its 
biochemical and physiological properties (reviewed in [2-4]). 
Pro-uPA activation, generation of inhibitor-resistant cell sur- 
face plasmin, internalization of the uPA/serpins complexes 
and direct signal transduction influencing cell migration and 
adhesion, are properties of uPA that are stimulated by or 
require the binding to uPAR [2-7]. Hence, binding to uPAR 
mediates the effect of uPA on extracellular proteolysis, cell 
migration and on the invasive and metastatic phenotype of 
cancer cells [2-4]. 
In uPA, the receptor-binding determinants are located in 
the amino terminus of the molecule, confined to the growth 
factor domain [8]. This information is not available for uPAR, 
which is a ca. 55 kDa glycoprotein, product of a 313 residues 
precursor protein [9,10]. The mature protein is processed at 
the carboxy terminus (Ser-282/Gly-283) and is substituted by 
a glycosyl-phosphatidylinositol (GPI) anchor so that the pro- 
tein remains attached to the plasma membrane in a form that 
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can be released by treatment with a bacterial phospholipase C 
[11,12]. N-linked glycosylation is responsible for about 40% of 
the molecular weight [10,13,14]. The position and spacing of 
cysteines within the amino acids sequence of uPAR has re- 
vealed a triple internal repetition, which led to the suggestion 
of a three-domain structure [15]. Each domain (D1, D2 and 
D3) is related to a family of single-repeat, GPI-anchored sur- 
face proteins that include CD59, the Ly-6 antigens as well as 
snake neurotoxins [15,16]. The disulfide bond pattern of D1 
conforms to the general structure of the Ly-6/neurotoxins 
protein family and has suggested overall structural homology 
to CD59 and snake a-bungarotoxin for which a tertiary struc- 
tural analysis is available [17-19]. The purified amino terminal 
domain (D1) of uPAR possesses independent ligand-binding 
activity, although with an affinity 1,500 fold lower than the 
wild type [1]; the purified carboxy-terminal fragment (D2D3) 
appears to be devoid of binding activity [1,15]. We have in- 
vestigated, therefore, the effect of removing domain D2 or D3 
on the binding properties of human uPAR. These mutants 
have been expressed in murine LB6 cells in a GPI-anchored 
form and found to display an about wild-type affinity for 
uPA. 
2. Materials and methods 
2.1. Materials 
Recombinant E. coli expressed ATF (the amino terminal fragment 
of uPA: residues 1-143) containing the receptor binding site, was a 
kind gift of Drs. Anna Brandazza nd Marco Soria (DIBIT, Milan). 
Pro-uPA was obtained from Lepetit SpA, courtesy of Dr. L. Nolli. 
Phosphatidylinositol-specific phospholipase C (PI-PLC) from B. cer- 
eus was from Boehringer Mannheim GmbH, Germany. Monoclonal 
antibodies R2 and R3 [20] were kind gifts from Drs. G. H~yer-Han- 
sen and E. R~nne. 
2.2. Cell culture and transJections 
Transfected cells were grown as described for LB6 clone 19 cells [9] 
in the presence of 0.04% G418. Transfections were carried out with 
the calcium phosphate precipitation technique [21]. Individual clones 
were isolated and those positive in immunofluorescence for mAb R3 
were chosen for further study. 
2.3. Mutants and plasmids construction 
In the following description, amino acid residues and nucleotide 
positions are taken from the previously published uPAR cDNA se- 
quence [9]. Construct DIHD3 was made from the uPAR EcoRV 
mutant in an Okayama-Berg vector [22]. The sequence coding for 
domain D2 (amino acids 93 191) was removed by PCR. As upstream 
primer, the sequence corresponding to nucleotides 32-60 of the hu- 
man uPAR cDNA was used. For the downstream primer, a sequence 
was used overlapping the 3' end of domain D1 (nucleotides 375 388) 
and the 5' end of domain D3 (nucleotides 685-711) thus looping out 
domain D2 (nucleotides 389-710). In addition, we have inserted be- 
tween residues 92 and 192, i.e. between DI and D3, the hinge region 
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Gly-Gly-Gly-Ser, by inserting the sequence ACTACCACCACC in the 
downstream primer. Both primers contained appropriate restriction 
sites (NruI and PvuII). The plasmid coding for the uPAR EcoRV 
mutant [22] was double digested with NruI and PvuII and replaced 
with the PCR product cut with the same enzymes. As a result, this 
construct contains a Gly-Gly-Gly-Ser hinge inserted between residues 
92 and 192, i.e. between D1 and D3. 
Construct D1D2, missing the 3rd domain, was constructed from the 
same starting plasmid as D1HD3. The sequence coding for domain 
D3 (amino acids 192-274) was removed by PCR using an upstream 
primer corresponding to position 32 60 and a downstream primer 
(nucleotides 670 684+935 956) looping out domain D3 and fusing 
domain D2 to the GPI-anchor attachment and signal sequence. The 
plasmid coding for the uPAR EeoRV mutant was double digested 
with NruI and EcoRV; the PCR product was also double digested 
with NruI and EcoRV. The cleaved plasmid and PCR product were 
ligated by standard methods. 
All mutations were verified by DNA sequencing of the PCR-cloned 
constructs and by restriction mapping of the junctions of the final 
expression clones. 
2.4. Immunofluorescence 
Cells were placed and grown on glass slides in 24 well plates. The 
medium was removed, the cells were fixed with 3% paraformaldehyde, 
washed and stained with anti-uPAR antibody R3 and then with rho- 
damine-conjugated swine anti-mouse IgG (Dakopatts). Co-staining 
with fluorescein-conjugated phalloidin was used to visualize actin. In 
the experiments in which the effect of PI-PLC was tested, the cells 
were incubated with 5 IU/ml of PI-PLC in D-MEM for 15 min at 
37°C, then washed with PBS containing 0.5 mM CaC12, 0.5 mM 
MgC12 and 0.1% BSA, fixed and processed as above. 
2.5. Binding assay 
Iodination of ATF with Iodogen (Pierce Chemical Co.) has been 
described before [10]; the iodinated ATF had a specific radioactivity 
of 75,000 to 150,000 cpm/ng, depending on the preparation. Cells 
were plated on gelatin coated 96 well plates (80,000 cells/well) one 
day before the experiment. On the day of experiment, he cells were 
incubated for 3045 min at 37°C in binding buffer (50 mM HEPES, 
pH 7, 0.1% BSA in D-MEM), then transferred on ice; the binding 
buffer was replaced with increasing concentrations of [125I]ATF in the 
presence or absence of 100 fold excess unlabeled pro-uPA or recom- 
binant ATF and the cells were incubated on ice for 3 h. The cells were 
washed 3 times with cold PBS containing 0.5 mM CaC12, 0.5 mM 
MgCI2 and 0.1% BSA. Then, 1% SDS was added and the radioactiv- 
ity in the SDS-lysate was measured. 
2.6. Metabolic labelling, immunoprecipitation a d SDS-PAGE 
Cells were metabolically abeled as previously described [23], with a 
15 min labeling with [asS]-TransLabel and a chase-time of 3 h. After 
lysis and preclearing of cell lysates, immunoprecipitation was per- 
formed using a mixture of mAbs R2 and R3 at 4°C [23]. Immuno- 
complexes were recovered with GammaBind G-Sepharose (Pharma- 
cia), resuspended in SDS-PAGE sample buffer, separated on 12.5% 
SDS-PAGE and autoradiographed. 
2. 7. Cross/&king of A TF to whole cells 
Cells were plated for 24 h on gelatin coated 6 well plates (500,000 
cells/well) as above. Cross-linking was performed as described before 
[13]. Briefly, on the day of the experiment the cells were incubated for 
30 min at 37°C in binding buffer and transferred on ice. Binding 
buffer was replaced with either 10 or 0.1 nM [125I]ATF in binding 
buffer and the cells were incubated on ice for 3 h. The cells were 
washed twice with cold PBS containing 0.5 mM CaCI2, 0.5 mM 
MgC12 and 0.1% BSA and incubated 15 min at room temperature 
with 2 mM N,N'-disuccinimidyl suberate (DSS) (Pierce Chemical 
Co.) in PBS; the reaction was stopped with 10 mM ammonium acet- 
ate. Then the cells were scraped from the wells and centrifuged. Re- 
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Fig. 1. Schematic representation f the three-domains wild type human uPAR and of the two deletion mutants. The numbers indicate amino 
acids residues in mature uPAR. The wavy line to the right shows the GPI-anchor. The rectangles represent the remaining domains, the lines 
the linker regions. Terminology on the right is based on which of the three domains is retained: DID2D3 is the symbol for wild type uPAR. 
Mutant D1HD3 contains a four amino acids, Gly-Gly-Gly-Ser hinge (indicated). 
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ducing SDS-PAGE sample buffer was added to the pellet, samples 
were boiled, run in 12.5% SDS-PAGE and the gel autoradiographed. 
3. Results and discussion 
Fig. 1 shows a schematic representation of the three-do- 
mains wild type human uPAR and of the two deletion mu- 
tants constructed. Notice that D1HD3 contains a four amino 
m-uPAR 
acids (Gly-Gly-Gly-Ser) linker-hinge region between D1 and 
D3. This hinge region was introduced after having failed to 
express a hinge-less D1D3 mutant possibly for improper fold- 
ing (data not shown). The sequence of the hinge region was 
chosen as this sequence appears to confer adequate mobility 
in other recombinant proteins made of two domains [24]. All 
constructs retain the N-terminal domain (D1) that can be 
specifically recognized by the R3 monoclonal antibody [20], 
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Fig. 2. Immunofluorescence analysis of the expression and PI-PLC sensitivity of transfected human uPAR and deletion mutants DID2 and 
D1HD3. Parental LB6 cells (m-uPAR) and LB6 cells expressing wild-type uPAR (D1D2D3), deletion mutant D1D2 or D1HD3 were either un- 
treated (-PI-PLC) or treated with 5 IU PI-PLC (+PI-PLC), incubated with mAb R3 (20 p.g/ml) and then stained with a rhodamine-conjugated 
anti-mouse IgG. FITC-phalloidin staining (not shown) was used to demonstrate he presence of cells in the uPAR-negative samples. 
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as well as the C-terminal sequence containing the GPI anchor- 
attachment and signal sequence [12]. Therefore all uPAR mu- 
tants can be recognized by antibody R3 in immunofluores- 
cence and should be sensitive to PI-PLC; sensitivity to PI- 
PLC should eliminate the positive immunofluorescence reac- 
tion, as a proof of cell-surface GPI-anchoring. 
Immunofluorescence with R3 antibody on non-permeabi- 
lized cells, treated or not with PI-PLC, was used to test for 
the expression of uPAR mutants on the surface of individual 
clones of LB6 cells. As shown in Fig. 2, the untransfected LB6 
cells expressing only murine uPAR (m-uPAR) did not yield a 
fluorescent signal, while all the others did. Treatment of each 
clone with PI-PLC resulted in the disappearance or clear re- 
duction of the R3-positive staining (Fig. 2). Therefore, we 
conclude that the mutants were expressed on the cell surface 
of LB6 cells and that they were PI-PLC sensitive and hence 
GPI-anchored to the membrane. 
We next estimated the molecular weight of the uPAR mu- 
tants by immunoprecipitation with anti-uPAR antibodies and 
SDS-PAGE analysis of ass-labeled extracts. Fig. 3A shows the 
SDS-PAGE analysis obtained after immunoprecipitation of 
the whole cell lysates. The lane labeled m-uPAR represents 
the negative control LB6 cells pattern. In comparison, LB6 
clone 19 (wild type uPAR, indicated as D1D2D3) gave the 
expected 45-55 kDa broad band characteristic of human 
uPAR [9-13,23]. Both mutants D1HD3 and D1D2 gave in- 
stead of a single band, two strong bands of about 30 and 35 
kDa (Fig. 3A, arrows). The 30 kDa band might represent 
incompletely glycosylated mutant uPAR, as observed intracel- 
lularly in other cells [10]. To check this point, DIHD3 and 
DID2 expressing cells were metabolically abeled with [a'~S] 
and treated with PI-PLC; both the lysed cell pellet and the 
PI-PLC supernatants were subjected to immunoprecipitation 
with anti-uPAR antibodies. Fig. 3B shows that the 30 kDa 
band was observed exclusively in the cell lysates of both mu- 
tants, while the higher molecular weight band was observed in 
the PI-PLC supernatant. Thus D1HD3 and D1D2 express 
both a PI-PLC sensitive, cell surface uPAR, and a PI-PLC 
resistant uPAR of lower molecular weight which might repre- 
sent intracellular, incompletely glycosylated molecules. There- 
fore, despite the high level of expression, only part of the two 
mutant receptors appears to be properly exposed. This beha- 
viour parallels that of PMA-treated human U937 cells in 
which a portion of the overexpressed uPA receptors is not 
properly glycosylated and does not reach the cell-surface [10]. 
We next analysed the ligand-binding properties of the 
uPAR mutants. We performed cross-linking analysis with 
DSS [13] on living cells after binding to 0.1 or 10 nM 
[12SI]ATF and analysed the formation of ATF-uPAR adducts 
by SDS-PAGE of the cell extracts and autoradiography. The 
formation of adducts of the expected size was observed with 
wild type uPAR-expressing cells as well as with the mutants 
D1HD3 and D1D2 at both ligand concentrations (Fig. 4A,B). 
The migration of the mutant adducts was faster than wild- 
type in agreement with the lower molecular weight of the 
mutant receptors. No specific adduct was observed in the 
case of the negative control LB6 cells. It must be noticed 
that at 0.1 nM ATF (Fig. 4B), visualization of a cross-linked 
adduct required a longer exposure time of the gel to the X-ray 
film in the mutants than in the wild type. 
In order to obtain quantitative information, binding iso- 
therm studies with whole cells at 4°C were carried out with 
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Fig. 3. Immunoprecipitation analysis of uPAR mutants expressed in LB6 cells. (A) Parental LB6 cells (m-uPAR) or LB6 cells expressing either 
wild-type uPAR (DID2D3), deletion mutant D1D2 or DIHD3 were pulse-labeled with [35S]-TransLabel for 15 min and chased for 3 h. Cells 
were lysed, immunoprecipitated with anti-uPAR antibodies R2 and R3 and analysed by SDS-PAGE. (B) aSS-labeled cells were pretreated with 
PI-PLC; both the lysed cell pellet and the PI-PLC supernatants were immunoprecipitated with anti-uPAR antibodies R2 and R3 and analysed 
by SDS-PAGE. Molecular weight markers are shown in kilodaltons on the left of each panel. 
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Table 1 
Analysis of the [125I]ATF-binding properties of LB6 cells expressing 
wild-type (D1D2D3), and mutant uPAR (D1HD3 and D1D2) a 
Construct n b Kd (nM) n uPAR c 
mean (+ S.D.) mean+ S.D. 
D1D2D3 6 2.62 (+ 1.1) 5.1 (+ 1,5)x10 s 
(wild type) 
D1HD3 2 7.9 1.6x 105 
D1D2 3 1.5 (+ 1.23) 0.92 (_+ 0.1) x l 05 
a[12SI]ATF binding was assessed by Scatchard analysis over a range of 
concentrations from 0.001 to 10 nM in triplicate wells. Specifity of 
binding was controlled in a parallel competition experiment by using a 
100-fold molar excess of unlabeled ATF. 
bNumber of experiments performed. 
CNumber of uPA receptors per cell. 
LB6 transfectants of wild type (D1D2D3) and mutant uPAR. 
Specific binding was defined as the amount of [lZSI]human 
ATF ligand that could be displaced in the presence of 100 
fold molar excess unlabeled human pro-uPA or recombinant 
ATF.  In all cases, specific binding amounted to at least 80% 
of total binding. The negative control LB6 cells displayed no 
specific binding at ATF  concentrations below 3 nM and very 
low levels (10~0% of total) at concentrations of 10 nM or 
more. Mutants D1D2 and D1HD3, however, displayed speci- 
fic binding for ATF  (again at least 80% of total binding). The 
binding isotherm data were subjected to Scatchard plot ana- 
lysis to calculate the affinity for ATF  and the number of 
receptors per cell. Representative data are reported in Table 
1. Wild-type uPAR-expressing cells displayed 513,000 recep- 
tors/cell, with a calculated Kd of about 2 nM, in agreement 
with previously published ata [14]. Mutant D1D2 displayed a
reduced binding capacity (91,000 receptors/cell), with an es- 
sentially identical binding affinity (1.5 nM), while mutant 
D1HD3 had a somewhat lower binding affinity, 7.9 nM, 
and 161,000 receptors/cell. 
These results show that mutant receptors displaying an 
about wild-type affinity can be generated even when domain 
D2 or D3 are deleted. Interestingly, our data show that do- 
main D2 and D3 are interchangeable in this respect, since a 
combination of D1 with both D2 or D3 yields a high affinity 
binding site. The difference in K,i measured between D1D2 
and D1HD3 (2 vs. 7 nM) may be due to folding problems 
in the latter, and in any case is only minor. However, the 
presence of all three domains is not required for attaining a 
wild-type binding affinity. 
The major ligand-binding domain of uPAR is located in 
domain D1 [15]. However, the isolated D1 domain has an 
over thousand fold lower affinity than the three-domains re- 
ceptor [1]. In conclusion, the behaviour of mutants D1D2 and 
D1HD3 suggests that the achievement of high ligand affinity 
requires at least two of the three domains. Since the isolated 
D2+D3 domain does not show any binding activity [1], the 
presence of domain DI is probably required to reach high 
affinity. However, D2 and D3 can inter-changeably cooperate 
with D1 to achieve high affinity. 
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